Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lab21 Partners with Top 10 IVD Player

Published: Wednesday, April 11, 2012
Last Updated: Wednesday, April 11, 2012
Bookmark and Share
Agreement to develop, manufacture and distribute new Aspergillus molecular assay.

Lab21 Limited has entered into an agreement with one of the world’s leading diagnostic businesses to develop, manufacture and distribute a diagnostic assay for the detection of Aspergillus species for the partner’s real time PCR platform.

Financial details of the agreement were not disclosed.

Under the agreement Lab21 will use its molecular diagnostic development resource and proprietary intellectual property in the fungal diagnostic area to develop and manufacture the new Aspergillus test as OEM reagents for the partner platform.

Graham Mullis, CEO of Lab21, commented: “We are pleased to enter into a new agreement to develop this assay. The MycAssay™ Aspergillus test provides rapid, accurate clinical information that allows health professionals to make life-saving treatment decisions quickly. This agreement follows closely behind the similar deal made with BD last year.”

Berwyn Clarke, CSO of Lab21, added: “The platform we will be using for the new assay is one which is becoming increasingly well adopted within clinical diagnostic laboratories worldwide. Independent clinical validation studies have already shown that both the new Lab21 Aspergillus and Pneumocystis assays are setting new standards in clinical diagnosis of these clinically important fungal pathogens. We expect the new assays to be significant components of the growing menu of our partner’s molecular diagnostic portfolio.”

Infection caused by Aspergillus is a leading cause of death in immunocompromised patients, with an estimated 10 million people at risk globally each year.

Studies have shown that diagnosis of Aspergillus infection followed by antifungal treatment within the first 10 days of infection reduces mortality from 90 percent to 40 percent - highlighting the need for rapid, accurate testing.

Real-time polymerase chain assays using Lab21 technology have been shown to provide significant advantages in sensitivity and specificity over the current culture techniques.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lab21 Among First to Offer FDA Approved Companion Diagnostic in the US
CLIA laboratory to provide guidance for the use of Erbitux®.
Monday, July 16, 2012
Lab21 Announces Appointment of Industry Expert Fraser Logue
Dr Logue joins Lab21 team as Group Director of Quality, Regulatory Affairs & Operations Excellence.
Tuesday, February 21, 2012
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!